SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

ANTHRASIL

EBS·Emergent BioSolutions Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since March 2015.
Why 4/10
ANTHRASIL is an already-approved, marketed product with no pending PDUFA date, no upcoming pivotal readout, and no scheduled regulatory decision. It is one of several products in Emergent's diversified biodefense portfolio. Per the scoring rubric, an approved drug with no imminent new regulatory decision scores 3-5; a 4 reflects that it is a mature commercial product without a binary catalyst.
Actionable Insight NEUTRAL

ANTHRASIL has no upcoming FDA catalyst. Watch Emergent's broader financial performance, government contract awards (particularly BARDA contracts for its anthrax vaccine CYFENDUS and smallpox products), and the company's restructuring progress. The stock's sharp post-earnings decline reflects company-wide revenue pressure, not ANTHRASIL-specific news.

Price Chart

Loading chart...

Executive Summary

ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)) is an FDA-approved therapeutic for inhalational anthrax, developed and marketed by Emergent BioSolutions Inc. (NYSE: EBS). Originally approved in March 2015, it is a polyclonal antibody therapy derived from human plasma that neutralizes anthrax toxins. The drug is stocked in the U.S. Strategic National Stockpile and sold primarily to government customers. ANTHRASIL is a mature, approved product with no upcoming regulatory catalysts; it is one of several biodefense products in Emergent's portfolio, which also includes anthrax vaccines (BioThrax, CYFENDUS), smallpox/mpox treatments, and naloxone. The company reported Q3 2026 earnings today (Nov 2, 2026) with revenue of $110M, a 52% YoY decline, and the stock fell sharply in after-hours trading.

How It Works

ANTHRASIL is a purified antibody solution made from the blood plasma of healthy donors who have been vaccinated against anthrax. It contains concentrated antibodies (immune proteins) that recognize and neutralize the toxins produced by Bacillus anthracis, the bacterium that causes anthrax. It is given intravenously (through a vein) alongside antibiotics to treat inhalational anthrax.

Trial Status

ANTHRASIL was approved by the FDA on March 24, 2015 (BLA 125562) based on efficacy studies in animal models of inhalational anthrax, supported by safety data from healthy human volunteers and limited expanded-access use in anthrax patients. It is a commercially marketed product stocked in the U.S. Strategic National Stockpile.

The Two-Sided Case

▲ Bull Case4
ANTHRASIL is the only FDA-licensed polyclonal antibody therapeutic for inhalational anthrax, giving it a unique position in the biodefense market.
The drug is part of the U.S. Strategic National Stockpile, providing recurring government procurement revenue.
Ongoing biodefense funding and geopolitical tensions support sustained government demand for anthrax medical countermeasures.
Multiple large institutional investors (Millennium Management, Goldman Sachs, Prudential) added or doubled their EBS positions in Q2 2026.
▼ Bear Case5
ANTHRASIL sales have been declining, with the company citing lower international sales (particularly to Canada) and the absence of international orders in recent quarters.
The drug's effectiveness is based solely on animal model studies, which limits its clinical evidence base and potential label expansion.
Emergent's overall financial performance is under severe pressure: Q3 2026 revenue fell 52% YoY to $110M, GAAP gross margin dropped to 14%, and the company reduced full-year 2026 guidance.
Insider sales occurred in October 2026 (director and officer sold shares under 10b5-1 plans), and the stock has fallen sharply, trading near its 52-week low.
ANTHRASIL is a small part of a challenged company facing restructuring, leadership transition, and pricing/volume headwinds in its naloxone and smallpox segments.

Upcoming Catalysts

  • None for ANTHRASIL specifically. For Emergent overall: continued BARDA contract awards for CYFENDUS anthrax vaccine and other biodefense products, and execution of the company's restructuring plan.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Emergent BioSolutions Inc. 8-K EBS ·Originating report

Sources · 11

Hover a chip for the title
1 fda.gov2 purplebooksearch.fda.gov3 drugs.com4 emergentbiosolutions.com5 investors.emergentbiosolutions.com6 sec.gov7 tradingkey.com8 marketbeat.com9 stocklight.com10 biospace.com11 biospace.com